Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2023

Open Access 01-12-2023 | Encephalopathy | Research

Clinical presentations and treatment outcomes of Hashimoto encephalopathy at Siriraj Hospital – Thailand’s largest national tertiary referral center

Authors: Chaisak Dumrikarnlert, Smathorn Thakolwiboon, Vorapun Senanarong

Published in: BMC Neurology | Issue 1/2023

Login to get access

Abstract

Background

Hashimoto encephalopathy has multiple clinical presentations, and other than the presence of thyroid antibody, laboratory and imaging investigations are all non-specific. Data specific to the clinical presentations and treatment outcomes of patients with Hashimoto encephalopathy in Thailand remain scarce.

Objectives

To retrospectively investigate the clinical presentations and treatment outcomes of patients with Hashimoto encephalopathy at Siriraj Hospital.

Methods

Patients who presented with acute encephalopathy at our center during July 2012-March 2017 were evaluated for eligibility. The inclusion criteria were positive anti-thyroperoxidase (anti-TPO) or anti-thyroglobulin (anti-Tg) in serum with negative neuronal antibody in serum or cerebral spinal fluid (CSF). Clinical presentations, symptom duration, laboratory results of thyroid status and thyroid autoantibody, CSF study, and clinical outcomes were collected.

Results

Of the 204 patients who presented with encephalopathy, 31 (15.2%) were positive for the anti-TPO or anti-Tg antibody. Of those, 13 patients met the diagnostic criteria for Hashimoto encephalopathy. Clinical presentations included cognitive impairment (76.9%), clouding of consciousness (46.2%), and behavior change (30.8%). The neuropsychiatric presentations were visual hallucination (30.8%), auditory hallucination (15.4%), delusion (7.7%), and mood disturbance (23.1%). Other clinical presentations included seizure (38.5%), abnormal movement (23.1%), sleep disturbance (38.5%), ataxia (46.2%), stroke-like episode (15.4%), and fever (15.4%). Most patients (76.9%) had onset within < 3 months. Regarding outcomes, 1 patient who did not receive corticosteroid died from status epilepticus and septic shock. Among the 12 patients who received corticosteroid, 9 (75%) had marked improvement, 1 (8.3%) had slight improvement, and 2 (16.6%) had no clinical improvement. Seven patients (53.9%) had normal thyroid function, 4 patients (30.8%) had subclinical hypothyroidism, and 2 patients (15.4%) had subclinical hyperthyroidism.

Conclusions

The results of this study revealed cognitive impairment, neuropsychiatric symptoms, seizure, ataxia, and sleep disturbance to be common manifestations of Hashimoto encephalopathy. This condition should always be considered in individuals with subacute onset of unexplained cognitive impairment or cerebellar ataxia. Laboratory and neuroimaging investigations were all found to be nonspecific in Hashimoto encephalopathy. Most patients responded well to treatment, so clinical suspicion and early diagnosis and treatment will lead to improved patient outcomes.
Appendix
Available only for authorised users
Literature
1.
Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch neurol. 2006;63:197–202.CrossRefPubMed
2.
Kothbauer-Margreiter I, Sturzenegger M, Komor J, et al. Encephalopathy associated with Hashimoto thyroiditis: diagnosis and treatment. J Neurol. 1996;243:585–93.CrossRefPubMed
3.
Afshari M, Afshari ZS, Schuele SU. Pearls & oy-sters: Hashimoto encephalopathy. Neurology. 2012;78:e134–7.CrossRefPubMed
4.
Matsunaga A, Ikawa M, FujiiA, et al. Hashimoto’s encephalopathy as a treatable adult-onset cerebellar ataxia mimicking spinocerebellar degeneration. Eur Neurol. 2013;69:14–20.CrossRefPubMed
5.
6.
7.
Waliszewska-Prosół M, Ejma M. Hashimoto Encephalopathy-Still more questions than answers. Cells 2022 Sep 14;11(18):2873.
8.
9.
Laurent C, Capron J, Quillerou B, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): characteristics, treatment and outcome in 251 cases from the literature. Autoimmun Rev. 2016;15:1129–33.CrossRefPubMed
10.
Marshall GA, Doyle JJ. Long-term treatment of Hashimoto’s encephalopathy. J Neuropsychiatry Clin Neurosci. 2006;18:14–20.CrossRefPubMed
11.
Chaudhuri A, Behan PO. The clinical spectrum, diagnosis, pathogenesis and treatment of Hashimoto’s encephalopathy (recurrent acute disseminated encephalomyelitis). Curr Med Chem. 2003;10:1945–53.PubMed
12.
Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2(7872):81–4.CrossRefPubMed
13.
14.
15.
Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol. 2003;60(2):164–71.CrossRefPubMed
16.
Mattozzi S, Sabater L, Escudero D, et al. Hashimoto encephalopathy in the 21st century. Neurology. 2020;94:e1–e8.CrossRef
17.
Sliwinska A, Fumuso P, Stringer B, et al. Hashimoto Encephalopathy With Status Epilepticus Cureus. 2020;12(12):e11857.PubMed
18.
Guasp M, Giné-Servén E, Maudes E, et al. Clinical, neuroimmunologic, and CSF investigations in First Episode Psychosis. Neurology. 2021;97(1):e61–e75.CrossRefPubMed
19.
Kayser MS, Titulaer MJ, Gresa-Arribas N, et al. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013;70(9):1133–9.CrossRefPubMed
20.
Höftberger R, van Sonderen A, Leypoldt F, et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology. 2015;84(24):2403–12.CrossRefPubMedPubMedCentral
21.
Lopez-Chiriboga AS, Komorowski L, Kümpfel T, et al. Metabotropic glutamate receptor type 1 autoimmunity: clinical features and treatment outcomes. Neurology. 2016;86(11):1009–13.CrossRefPubMedPubMedCentral
22.
Shaw PJ, Walls TJ, Newman PK, et al. Hashimoto’s encephalopathy: a steroid-responsive disorder associated with high anti-thyroid antibody titers—report of 5 cases. Neurology. 1991;41(2pt1):228–33.CrossRefPubMed
23.
Alazzeh A, Jaroudi S, Gooch M et al. Focal neurological presentation in Hashimoto’s encephalopathy mimicking a vascular occlusion of the middle cerebral artery.BMJ Case Rep 2017; 2017:bcr-2017-219933.
24.
Graham BR, Shiff N, Nour M, et al. Hashimoto Encephalopathy presenting with Stroke-Like episodes in an adolescent female: a case report and literature review. Pediatr Neurol. 2016;59:62–70.CrossRefPubMed
25.
Valencia-Sanchez C, Pittock SJ, Mead-Harvey C, et al. Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Commun. 2021;3(2):fcaa233.CrossRefPubMedPubMedCentral
26.
Ferracci F, Carnevale A. The neurological disorder associated with thyroid autoimmunity. J Neurol. 2006;253(8):975–84.CrossRefPubMed
27.
Zhu Y, Yang H, Xiao F. Hashimoto’s encephalopathy: a report of three cases and relevant literature reviews. Int J Clin Exp Med. 2015;8(9):16817–26.PubMedPubMedCentral
28.
Kelley BP, Patel SC, Marin HL, et al. Autoimmune encephalitis: pathophysiology and imaging review of an overlooked diagnosis. AJNR Am J Neuroradiol. 2017;38:1070–8.CrossRefPubMedPubMedCentral
29.
Mocellin R, Walterfang M, Velakoulis D, et al. Hashimoto’s encephalopathy: epidemiology, pathogenesis and management. CNS Drugs. 2007;21(10):799–811.CrossRefPubMed
30.
Jegatheeswaran V, Chan M, Chen YA. MRI findings of two patients with Hashimoto Encephalopathy. Cureus. 2021;13(6):e15697.PubMedPubMedCentral
31.
Ochi H, Horiuchi I, Araki N, et al. Proteomic analysis of human brain identifies alpha-enolase as a novel autoantigen in Hashimoto encephalopathy. FEBS Lett. 2002;528:197–202.CrossRefPubMed
32.
Fujii A, Yoneda M, Ito T, et al. Autoantibodies against the amino terminal of α-enolase are a useful diagnostic marker of Hashimoto encephalopathy. J Neuroimmunol. 2005;162:130–6.CrossRefPubMed
33.
Yoneda M, Fujii A, Ito A, et al. High prevalence of serum autoantibodies against the amino terminal of alpha-enolase in Hashimoto encephalopathy. J Neuroimmunol. 2007;185(1–2):195–200.CrossRefPubMed
34.
Terrier B, Degand N, Guilpain P, et al. Alpha-enolase: a target of antibodies in infectious and autoimmune diseases. Autoimmun Rev. 2007;6(3):176–82.CrossRefPubMed
35.
Sechi E, Flanagan EP. Antibody-mediated Autoimmune Diseases of the CNS: Challenges and Approaches to diagnosis and management. Front Neurol. 2021;12:673339.CrossRefPubMedPubMedCentral
36.
Dupont S. Non convulsive status epilepticus in the elderly. Geriatr Psychol Neuropsychiatr Vieil. 2019;17(S1):25–30.PubMed
37.
Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, et al. Autoimmune encephalitis misdiagnosis in adults. JAMA Neurol. 2023;80(1):30–9.CrossRefPubMed
38.
Valencia-Sanchez C, Pittock SJ, Mead-Harvey C, et al. Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Commun. 2021;3(2):fcaa233.CrossRefPubMedPubMedCentral
39.
Litmeier S, Pruss H, Witsch E, et al. Initial serum thyroid peroxidase antibodies and long-term outcomes in SREAT. Acta Neurol Scand. 2016;134:452–7.CrossRefPubMed
40.
Riangwiwat T, Sangtian J, Sriphrapradang C. Steroid-responsive encephalopathy: an under recognized aspect of Hashimoto’s thyroiditis. Case Reports 2015; 2015: bcr2014208969.
41.
Termsarasab P, Pitakpatapee Y, Frucht SJ et al. Steroid-responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT) presenting with pure cerebellar Ataxia. Tremor Other Hyperkinet Mov (N Y) 2018; 8: 585.
42.
Charoensri A, Tunlayadechanont S, Apiwattanakul M, et al. Autoimmune antibody in encephalopathic patients: a pilot study. J Med Assoc Thai. 2021;104:943–50.CrossRef
43.
Sharma PM, Javali M, Mahale R, et al. Hashimoto encephalopathy: a study of the clinical profile, radiological and electrophysiological correlation in a Tertiary Care Center in South India. J Neurosci Rural Pract. 2015;6(3):309–14.CrossRefPubMedPubMedCentral
Metadata
Title
Clinical presentations and treatment outcomes of Hashimoto encephalopathy at Siriraj Hospital – Thailand’s largest national tertiary referral center
Authors
Chaisak Dumrikarnlert
Smathorn Thakolwiboon
Vorapun Senanarong
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-023-03305-4

Other articles of this Issue 1/2023

BMC Neurology 1/2023 Go to the issue

Case Report

Secondary polycythaemia from chronic hypoxia is a risk for cerebral thrombosis: a case report

Case report

Ectopic invasive ACTH-secreting pituitary adenoma mimicking chordoma: a case report and literature review

Research

Prevalence and factors associated with pre-hospital delay among acute stroke patients at Mulago and Kiruddu national referral hospitals, Kampala: a cross-sectional study

Study Protocol

COVCOG: Immediate and long-term cognitive improvement after cognitive versus emotion management psychoeducation programs - a randomized trial in covid patients with neuropsychological difficulties

Research

Risk factors for early neurologic deterioration in single small subcortical infarction without carrier artery stenosis: predictors at the early stage

Case report

Synovial sarcoma of the tibial nerve - case report of a rare tumor in a rare location requiring early diagnosis